About Amal Therapeutics

Sponsor retains sole responsibility for content.

AMAL Therapeutics SA is a spin-off from the University of Geneva active in cancer immunotherapy. AMAL has developed a unique protein-based immunization platform called KISIMA® providing activation signal to dendritic cells simultaneously to priming both helper and killer cells for various antigens and HLA restrictions. This first-in-class platform is offering the opportunity to develop standardize...

AMAL Therapeutics SA is a spin-off from the University of Geneva active in cancer immunotherapy. AMAL has developed a unique protein-based immunization platform called KISIMA® providing activation signal to dendritic cells simultaneously to priming both helper and killer cells for various antigens and HLA restrictions. This first-in-class platform is offering the opportunity to develop standardized and indicationtailored active immunotherapies. The company’s lead product ATP128 is currently being developed for metastatic and advanced colorectal cancer.

Contact Amal Therapeutics

Phone Number
+41 22 379 46 88

More About Amal Therapeutics

Therapeutic Areas
  • Oncology
Technologies
  • Vaccines
Company Type
  • Biotechnology – Therapeutics
State of Ownership
  • Private
Sponsorship Group
  • Networker